These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2685505)

  • 21. [Musculoskeletal lymphomas].
    Ludwig K
    Radiologe; 2002 Dec; 42(12):988-92. PubMed ID: 12486552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
    Urquhart A; Berg R
    Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant lymphomas that mimic benign lymphoid lesions: a review of four lymphomas.
    Wilson CS; Chang KL; Weiss LM
    Semin Diagn Pathol; 1995 Feb; 12(1):77-86. PubMed ID: 7770676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
    Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
    Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant lymphomas in Korea.
    Chi JG; Shin SS; Ahn GH; Lee SK
    Jpn J Clin Oncol; 1985 Dec; 15(4):653-9. PubMed ID: 4094098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic assessment of enlarged superficial lymph nodes by fine needle aspiration.
    Pilotti S; Di Palma S; Alasio L; Bartoli C; Rilke F
    Acta Cytol; 1993; 37(6):853-66. PubMed ID: 8249502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Lymphoid depletion type 4 Hodgkin disease. Anatomoclinical review of 35 cases].
    Eghbali H; Pétorin C; de Mascarel I; Trojani M; Hoerni-Simon G; Soubeyran P; Hoerni B
    Bull Cancer; 1994 Oct; 81(10):866-70. PubMed ID: 7734769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
    Bien E; Balcerska A
    Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Beta 2 microglobulin].
    Clément F
    Schweiz Med Wochenschr; 1983 Jun; 113(23):838-43. PubMed ID: 6192496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The different expression of key-molecules allows the easy subclassification of Hodgkin's lymphoma cases as well as their distinction from non-Hodgkin's lymphomas.
    Pileri SA; Marafioti T; Pozzobon M; Sabattini E; Ascani S; Mancini C; Piccioli M; Hansmann ML; Delsol G; Mason DY
    Pathologica; 2003 Oct; 95(5):227. PubMed ID: 14988978
    [No Abstract]   [Full Text] [Related]  

  • 32. Malignant lymphoma in western Ethiopia.
    Getachew A
    East Afr Med J; 2001 Aug; 78(8):402-4. PubMed ID: 11921560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant lymphoma: an update on diagnosis, staging, and management.
    Perlin E
    Prim Care; 1980 Sep; 7(3):409-22. PubMed ID: 6905202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Nucleolar organizer as a marker of malignancy grade and prognosis of non-Hodgkin's malignant lymphoma].
    Raĭkhlin NT; Bukaeva IA; Probatova NA; Smirnova EA; Tupitsyn NN; Sholokhova EN
    Arkh Patol; 1996; 58(4):22-8. PubMed ID: 8967858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
    Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
    Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [ORL manifestations in malignant hemopathies].
    Koffi-Aka V; Akon JC; Koné M; Yotio A; Ehouo F
    Rev Laryngol Otol Rhinol (Bord); 1999; 120(2):97-101. PubMed ID: 10444982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parathyroid-hormone-related peptide in hematologic malignancies.
    Kremer R; Shustik C; Tabak T; Papavasiliou V; Goltzman D
    Am J Med; 1996 Apr; 100(4):406-11. PubMed ID: 8610726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
    Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Karkantaris C; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Pizzolo G; Pangalis GA
    Haematologica; 2002 Jul; 87(7):701-8; discussion 708. PubMed ID: 12091120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Malignant and benign lymphomas: histologic classification and immunomorphologic studies. Results of 838 cases].
    Radaszkiewicz T
    Wien Klin Wochenschr; 1980 Dec; 92(23):819-33. PubMed ID: 6985528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Malignant lymphomas (non-Hodgkin's lymphomas and Hodgkin's disease) associated with infection by the human immunodeficiency virus. Study of 9 cases].
    Lozano-Molero M; Ribera JM; Nomdedeu B; Llebaría C; Campo E; Montserrat E; Rozman C
    Med Clin (Barc); 1989 Mar; 92(8):302-5. PubMed ID: 2716418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.